Filing Flows › Aligos Therapeutics (ALGS) › Q2 2025
Aligos Therapeutics (ALGS) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 6, 2025
Aligos Therapeutics (ALGS) reported revenue of $965K for the second quarter 2025 (Q2 2025), -9% from a year earlier and +210% from the quarter before.
Aligos Therapeutics, Q2 2025: revenue $965K (-9% year over year), net loss $15.9M, operating cash flow −$15.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $965K | +210% | -9% |
| Operating profit | −$18.6M | — | — |
| Net earnings | −$15.9M | -137% | — |
| Operating cash flow | −$15.5M | — | — |
What changed
Revenue was $1.0M in Q2 2025, down 9% year over year and up 210% from the previous quarter.
Operating costs exceeded revenue by $18.6M, an operating margin of -1924.0%. Total costs fell 29% while revenue fell 9%. The quarter ended with a net loss of $15.9M, after a profit of $43.1M the previous quarter.
Operating cash flow was −$15.5M. Non-cash charges added back $300K of depreciation and $1.2M of share-based compensation. Working capital and other items used $1.1M.
Questions
What was Aligos Therapeutics' revenue in the second quarter 2025?
Aligos Therapeutics (ALGS) reported revenue of $965K for the second quarter 2025 (Q2 2025), -9% from a year earlier and +210% from the quarter before.